West Pharmaceutical Services, Inc. (WST) Financial Statements
West Pharmaceutical Services, Inc. (WST) reported trailing twelve-month revenue of $3.3B (up 12.4% year on year) and net income of $564.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $436.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
WSTWest Pharmaceutical Services, Inc.Follow WST — free
—
Price chart with a free account
- Market cap
- 27.6B
- P/E TTM
- 50.2
- Dividend yield
- 0.2%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.10 | 1.19 | 1.27 | 1.37 | 1.42 | 1.40 | 1.51 | 1.60 | 1.72 | 1.84 | 2.15 | 2.83 | 2.89 | 2.95 | 2.89 | 3.07 | 3.33 | |
| Gross profit | 0.32 | 0.34 | 0.39 | 0.43 | 0.45 | 0.46 | 0.50 | 0.51 | 0.55 | 0.61 | 0.77 | 1.18 | 1.14 | 1.13 | 1.00 | 1.10 | 1.22 | |
| Research & development | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | |
| Operating income | 0.09 | 0.11 | 0.14 | 0.16 | 0.18 | 0.13 | 0.20 | 0.23 | 0.24 | 0.30 | 0.41 | 0.75 | 0.73 | 0.68 | 0.57 | 0.58 | 0.68 | |
| Pre-tax income | 0.07 | 0.09 | 0.11 | 0.15 | 0.17 | 0.12 | 0.19 | 0.22 | 0.24 | 0.29 | 0.40 | 0.75 | 0.68 | 0.70 | 0.59 | 0.60 | 0.69 | |
| Income tax | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.03 | 0.05 | 0.08 | 0.04 | 0.06 | 0.07 | 0.11 | 0.11 | 0.12 | 0.11 | 0.12 | 0.14 | |
| Net income | 0.07 | 0.08 | 0.08 | 0.11 | 0.13 | 0.10 | 0.14 | 0.15 | 0.21 | 0.24 | 0.35 | 0.66 | 0.59 | 0.59 | 0.49 | 0.49 | 0.56 | |
| Diluted EPS ($) | 1.89 | 1.08 | 1.15 | 1.57 | 1.75 | 1.30 | 1.91 | 1.99 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 | 6.69 | 6.79 | 7.81 | |
| Diluted shares (bn) | 0.037 | 0.074 | 0.072 | 0.071 | 0.073 | 0.074 | 0.075 | 0.076 | 0.075 | 0.075 | 0.076 | 0.076 | 0.076 | 0.075 | 0.074 | 0.073 | — |
USD billions · SEC XBRL
West Pharmaceutical Services, Inc. — questions
- What is West Pharmaceutical Services, Inc.'s revenue?
- $3.3B over the twelve months to 2026-06-30, up 12.4% year on year, from its 10-Q and 10-K filings.
- What is West Pharmaceutical Services, Inc.'s net income?
- $564.9M over the twelve months to 2026-06-30.
- What is West Pharmaceutical Services, Inc.'s free cash flow?
- $436.9M over the twelve months to 2026-06-30.
- What are West Pharmaceutical Services, Inc.'s diluted earnings per share?
- $7.81 over the twelve months to 2026-06-30.
Every figure on this page comes from West Pharmaceutical Services, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.